APRINOIA Therapeutics

Executive Summary

APRINOIA Therapeutics is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to developing novel small-molecule therapeutics and companion diagnostics for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. The company targets protein misfolding pathologies, leveraging an integrated pipeline that includes both therapeutic candidates and diagnostic agents to enable early detection and treatment. Founded in 2016, APRINOIA has advanced its lead programs into Phase 2 clinical trials, demonstrating progress in addressing the high unmet need in neurodegenerative disorders. With a focus on precision medicine through paired diagnostics, the company aims to improve patient outcomes and potentially slow disease progression. As a private entity, APRINOIA continues to attract attention in the neuroscience space, though financial details remain undisclosed.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead Alzheimer's therapeutic candidate40% success
• Q1 2027Regulatory submission for companion diagnostic in China50% success
• Q3 2026Potential partnership or licensing deal for Parkinson's program30% success